Abstract
Administering radioligand therapy: day-of-delivery workflow and radiation safety precautions
NCODA Oncology and Hematology Meeting Abstracts, Vol.1(Supplement 1), p.a47
06/15/2026
DOI: 10.67209/DPGR8154
Abstract
Ripretinib is a switch-control tyrosine kinase inhibitor approved for patients with gastrointestinal stromal tumor (GIST) who received prior treatment with 3 or more kinase inhibitors, including imatinib. Sunitinib is approved for advanced GIST after imatinib failure. In an exploratory analysis of baseline circulating tumor deoxyribonucleic acid (ctDNA) from the INTRIGUE trial, patients with primary mutations in KIT exon 11 and secondary mutations exclusively in KIT exons 17/18 (KIT exon 11 + 17/18) received clinical benefit from ripretinib but not sunitinib (Heinrich MC, et al.; Nat Med. 2024). We present the final overall survival (OS) analysis and updated safety data in these patients.
Details
- Title: Subtitle
- Administering radioligand therapy: day-of-delivery workflow and radiation safety precautions
- Creators
- Dustin L. Boothe - Intermountain HealthcareJose De La CerdaStephen A. Graves - University of IowaShilpa Gupta - Cleveland ClinicLynn Huynh - The University of Texas MD Anderson Cancer CenterErik S. Mittra - Oregon Health & Science University
- Resource Type
- Abstract
- Publication Details
- NCODA Oncology and Hematology Meeting Abstracts, Vol.1(Supplement 1), p.a47
- DOI
- 10.67209/DPGR8154
- ISSN
- 3071-6462
- eISSN
- 3071-6462
- Publisher
- NCODA
- Language
- English
- Date published
- 06/15/2026
- Academic Unit
- Radiology; Radiation Oncology
- Record Identifier
- 9985219320102771
Metrics
1 Record Views